RxDoctor Payments Data

Stephanie Frisbie, MD

Family Medicine · van Buren, ARNPI 1043208879

Payments from drug & device makers

$8,166in general payments, 2019–2025

Across 559 payments — averaging $14.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Novo Nordisk$901
  • Lilly USA, LLC$540
  • Amgen$512
  • GSK$467
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$8,06199%
  • Education$1051%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,166 in reported general payments places this provider in the 90th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$164,008
Medicare patients
385
Services billed
3,262

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide64$79,831
EliquisApixaban90$78,868
Trelegy ElliptaFluticasone/Umeclidin/Vilanter78$77,878
MounjaroTirzepatide44$48,039
JanuviaSitagliptin Phosphate33$43,016
Breztri AerosphereBudesonide/Glycopyr/Formoterol50$38,172
LinzessLinaclotide32$27,558
MyrbetriqMirabegron34$25,947
JardianceEmpagliflozin17$22,444
TrulicityDulaglutide15$18,249
XareltoRivaroxaban20$17,653
SymbicortBudesonide/Formoterol Fumarate56$15,395
Tresiba Flextouch U-100Insulin Degludec12$14,709
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog15$14,110
FarxigaDapagliflozin Propanediol18$10,032

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$901$79,83164 claims
PfizerEliquis$461$78,86890 claims
GSKTrelegy Ellipta$467$77,87878 claims
Lilly USA, LLCMounjaro, Trulicity$540$66,28859 claims
AstraZenecaBreztri Aerosphere, Symbicort, Farxiga$1,012$63,600124 claims
MerckJanuvia$34$43,01633 claims
AbbVieLinzess, Synthroid$1,559$29,86154 claims
Astellas Pharma US IncMyrbetriq$113$25,94734 claims
Boehringer IngelheimJardiance$206$22,44417 claims
Johnson & JohnsonXarelto$128$17,65320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in van Buren

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →